Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Medical Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,383.646 |
Reported balance
After 2026-08-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 3,040 · Balance 216,383.646 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025. F2: Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.
F2: Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,040 | $23.23 | $70,619.20 |
DisclosureSEC source: 0001628280-26-057759 · wk-form4_1787088074.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,383.646 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025. F2 · balance_after: Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 4,728 | $22.32 | $105,528.96 |
DisclosureSEC source: 0001628280-26-041331 · wk-form4_1780696625.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,912.175 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,261 | $22.82 | $74,416.02 |
DisclosureSEC source: 0001628280-26-019891 · wk-form4_1773956586.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,640.175 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 54,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008075 · wk-form4_1771016513.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,901.175 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 6,168 | $20.54 | $126,690.72 |
DisclosureSEC source: 0001628280-26-005155 · wk-form4_1770161031.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,355.175 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 381 | $24.46 | $9,319.26 |
DisclosureSEC source: 0001628280-26-000968 · wk-form4_1767738651.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,523.175 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. F2 · balance_after: Includes 537.166 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,960 | $24.09 | $95,396.40 |
DisclosureSEC source: 0001628280-25-053205 · wk-form4_1763587920.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,367.009 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 20:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 315 | $22.07 | $6,952.05 |
DisclosureSEC source: 0001396814-25-000095 · wk-form4_1754339458.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,327.009 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. F2 · balance_after: Includes 682.498 shares of common stock acquired under the issuer's employee stock purchase plan in June 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 5,084 | $26.40 | $134,217.60 |
DisclosureSEC source: 0001396814-25-000067 · wk-form4_1749159413.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,959.511 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 23:26 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 93,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000033 · wk-form4_1738711558.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,043.511 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 23:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 879 | $18.40 | $16,173.60 |
DisclosureSEC source: 0001396814-25-000007 · wk-form4_1736205784.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,443.511 F3 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 371 | $18.33 | $6,800.43 |
DisclosureSEC source: 0001396814-25-000007 · wk-form4_1736205784.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,322.511 F1 · kind: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 386.765 shares of common stock acquired under the issuer's employee stock purchase plan in December 2024. Read SEC document |
| August 02, 2024 Filed Aug 2, 2024 22:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 945 | $20.05 | $18,947.25 |
DisclosureSEC source: 0001396814-24-000100 · wk-form4_1722636050.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,306.746 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 22:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 305 | $20.75 | $6,328.75 |
DisclosureSEC source: 0001396814-24-000100 · wk-form4_1722636050.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,251.746 F1 · kind: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 22:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,836 | $28.25 | $80,117.00 |
DisclosureSEC source: 0001396814-24-000088 · wk-form4_1720047136.xml · nonDerivative · entry 3 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,556.746 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 22:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 914 | $28.46 | $26,012.44 |
DisclosureSEC source: 0001396814-24-000088 · wk-form4_1720047136.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,392.746 F2 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 22:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 437.271 | $24.32 | $10,633.99 |
DisclosureSEC source: 0001396814-24-000088 · wk-form4_1720047136.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,306.746 F1 · kind: Represents shares of common stock acquired under the issuer's employee stock purchase plan in June 2024. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 54,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000084 · wk-form4_1718316890.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,869.475 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,012 | $28.57 | $143,192.84 |
DisclosureSEC source: 0001396814-24-000084 · wk-form4_1718316890.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,569.475 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:09 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 1,615 | $30.89 | $49,887.35 |
DisclosureSEC source: 0001396814-24-000051 · wk-form4_1717621737.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,581.475 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 22:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0001396814-24-000013 · wk-form4_1704407065.xml · derivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-03 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000013 · wk-form4_1704407065.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,196.475 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 311.535 shares of common stock acquired under the issuer's employee stock purchase plan in December 2023. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 490 | $37.87 | $18,553.85 |
DisclosureSEC source: 0001209191-23-035263 · doc4.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,323 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 471 | $38.99 | $18,364.76 |
DisclosureSEC source: 0001209191-23-035263 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,813 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 205 shares of common stock acquired under the issuer's employee stock purchase plan in December 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:04 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 308 | $55.70 | $17,155.60 |
DisclosureSEC source: 0001209191-22-044554 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,079 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 23:04 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 924 | $57.19 | $52,841.71 |
DisclosureSEC source: 0001209191-22-041521 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,387 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 214 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleStock Option (Right to Buy) · Derivative | 24,800 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035232 · doc4.xml · derivative · entry 3 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2032-06-08 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035232 · doc4.xml · nonDerivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,097 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 362 | $61.37 | $22,217.39 |
DisclosureSEC source: 0001209191-22-035232 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,197 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $52.37 | $0.00 |
DisclosureSEC source: 0001209191-22-031854 · doc4.xml · derivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 2,000 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,000 | $52.37 | $104,740.00 |
DisclosureSEC source: 0001209191-22-031854 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 209 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:29 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $60.79 | $0.00 |
DisclosureSEC source: 0001209191-21-049940 · doc4.xml · derivative · entry 2 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-20 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on July 20, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:29 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049940 · doc4.xml · nonDerivative · entry 1 SLONIN JONATHAN · CIK 0001875723 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,350 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on August 1, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.